CompanyGreenLight Biosciences Holdings, PBC
United States of America
GreenLight Biosciences is a Medford, MA-based life science company committed to ensuring sustainable global development with bioprocessed RNA. GreenLight is currently developing bpRNA products in agricultural and health applications, and collaborating with industry leaders, to pave the way for advancements in vaccine development, pandemic preparation, crop management, and crop pesticides.
Private/Public:
public
Phone:+1(617)-616-8188
Email:[email protected]
Website:https://www.greenlightbiosciences.com/
Address:200 Boston Avenue
Suite 1000
Medford, MA 02155, United States of America
API/Biologicals Production
API/Biologics development and manufacturing
United States of America
- (14.Mar.2022) GreenLight Biosciences Holdings, PBC (GRNA) Enters Into Multitarget Licensing Agreement With Serum Institute of India to Develop and Commercialize Messenger RNA Products for Emerging Markets Globally
- (07.Feb.2022) GreenLight Agrees to Establish Field Station in Spain to Boost Research and Development for Key Plant Health Projects
- (03.Feb.2022) GreenLight Biosciences Begins Trading Today as Nasdaq: GRNA on the Closing of Its Business Combination With Environmental Impact Acquisition Corp
- (02.Feb.2022) Environmental Impact Acquisition Corporation Approval Obtained; GreenLight Biosciences Set to Begin Trading Under Nasdaq: GRNA on February 3, 2022
- (28.Jan.2022) ENVI Announces Quorum to Pass Business Combination With GreenLight Biosciences and Achievement of All Transaction Requirements Following the Redemption Deadline
- (14.Jan.2022) ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination
- (07.Jan.2022) GreenLight Biosciences Expands RTP Footprint for the Next Generation of Agricultural Products
- (05.Jan.2022) GreenLight and ENVI Announce a Recent Financing to Support Their Pending Business Combination
- (09.Dec.2021) The Boston Globe Names GreenLight Biosciences a Top Place to Work for 2021
- (03.Dec.2021) GreenLight (ENVI) and IAVI Begin Work on Omicron Variant-Adapted COVID-19 Vaccine Candidate
- (30.Nov.2021) GreenLight Biosciences (ENVI) Partners With IAVI to Accelerate COVID-19 Vaccine Trial in Africa
- (24.Nov.2021) GreenLight Biosciences and Samsung Biologics Announce Collaboration to Build Capacity for Messenger RNA Vaccine Manufacturing
- (23.Nov.2021) Serum Life Sciences Invests in RNA Biotech GreenLight by Joining Expanded Financing for Environmental Impact Acquisition Corp
- (19.Oct.2021) Greenlight Biosciences (ENVI) Science Day Updates Investors on Progress Across Human, Plant and Animal Health
- (21.Sep.2021) GreenLight Biosciences Opens RNA Production Facility for the Next Generation of Agricultural Products
- (11.Aug.2021) GreenLight Biosciences Announces Business Agreement With Environmental Impact Acquisition Corp. To Become Publicly Traded Company, Allowing It to Better Harness Its Breakthrough Platform to Develop and Produce RNA for Human Therapies and Agriculture